CC
Chemours Co
14.50$
+1.9%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -7.6% | -6.9% | -6.2% | -11.1% | -5.5% | +14.5% | +7.4% | -16.8% | -10.1% | +27.7% | +7.7% | -11.0% | -4.9% | +0.4% | |
| – | -6.7% | +7.6% | -6.0% | -6.1% | -9.9% | +3.2% | +5.4% | -4.4% | -12.6% | +27.2% | +5.1% | -8.5% | -3.0% | +5.9% | |
| – | -9.5% | -37.7% | -7.1% | -29.8% | +16.2% | +58.0% | +12.4% | -46.1% | +0.4% | +29.4% | +17.0% | -19.2% | -11.9% | -21.6% | |
| – | +7.4% | +13.1% | -12.8% | -32.2% | -17.5% | +0.0% | +2.5% | -2.4% | +16.3% | +15.1% | +10.3% | -8.5% | +0.9% | -0.9% | |
| – | +2.2% | +2.8% | -10.8% | -7.7% | +47.8% | -35.5% | +9.1% | -16.6% | -3.8% | +12.3% | +19.9% | +81.7% | -54.7% | +36.6% | |
| – | +3.0% | +4.5% | -11.2% | -12.0% | +39.1% | -32.7% | +8.4% | -16.6% | +0.5% | +14.2% | +17.4% | +72.2% | -50.5% | +28.1% | |
| – | -15.7% | -63.5% | +0.0% | -57.5% | -57.5% | +1,016.7% | +14.9% | -63.7% | +0.2% | +50.4% | +16.6% | -115.6% | – | -101.1% | |
| – | – | – | – | – | +65.9% | -1.8% | -9.3% | +6.7% | +1.0% | -11.9% | -11.9% | +27.6% | +26.9% | +1.9% | |
| – | -22.1% | -61.2% | -4.5% | -134.2% | – | – | +26.6% | -98.3% | +795.0% | +277.7% | +9.6% | -142.9% | – | -318.1% | |
| – | -9.9% | -64.4% | -2.0% | -165.8% | – | – | -3.6% | -54.7% | -155.6% | – | +139.7% | -149.7% | – | +165.9% | |
| – | -26.1% | -60.0% | -5.4% | -122.5% | – | +10,557.1% | +33.4% | -105.2% | – | +177.6% | -4.9% | -141.2% | – | -548.8% | |
| – | -13.9% | -54.0% | -0.5% | -73.3% | +238.9% | +88.1% | +14.7% | -53.7% | +7.3% | +53.6% | +1.4% | -83.5% | +251.3% | -52.0% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.